Increased activation of the Rho-A/Rho-Kinase pathway in the renal vascular system is responsible for the enhanced reactivity to exogenous vasopressin in endotoxemic rats

Critical Care Medicine

Volumn 42, Issue 6, 2014, Pages

  Guarido, Karla L ^a   Gonçalves, Ronald P M ^a   Gasparotto, Arquimedes ^b   Da Silva Santos, José Eduardo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE PARANAENSE   (Brazil)

Author keywords

Antidiuretic hormone; conductance catheter; kidney; renal blood flow; septic shock

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ARGIPRESSIN; LIPOPOLYSACCHARIDE; MYOSIN PHOSPHATASE; MYPT 1 PROTEIN; NITRATE; NITRITE; PHOSPHATASE; PROTEIN; RHO A PROTEIN; RHO FACTOR; RHO KINASE; ROCK PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART FUNCTION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PERFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERFUSION PRESSURE; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SEPTIC SHOCK; SIGNAL TRANSDUCTION; URINALYSIS; VASCULAR RING; WESTERN BLOTTING;

AMIDES; ANALYSIS OF VARIANCE; ANIMALS; ARTERIAL PRESSURE; ENDOTOXEMIA; ENZYME INHIBITORS; HEART; KIDNEY; MALE; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PERFUSION; PHENYLEPHRINE; PYRIDINES; RATS; RATS, WISTAR; RENAL CIRCULATION; RHO-ASSOCIATED KINASES; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84901500330     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000313     Document Type: Article

References (39)

1. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
2. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American Col lege of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association fo r Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: In ternational guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
3. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
4. Liedel JL, Meadow W, Nachman J, et al: Use of vasopressin in refractory hypotension in children with vasodil atory shock: Five cases and a review of the literature. Pediatr Crit Care Med 2002; 3:15-18
5. Tsuneyoshi I, Yamada H, Kakihana Y, et al: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493
6. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27:1416-1421
7. Tarpey SB, Bennett T, Randall MD, et al: Differential effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin II and arginine vasopressin in conscious rats. Br J Pharmacol 1998; 123:1367-1374
8. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
9. Bauer J, Parekh N: Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Kidney Int 2003; 63:2178-2186
10. Martinsen A, Baeyens N, Yerna X, et al: Rho kinase regulation of vasopressin-induced calcium entry in vascular smooth muscle cell: Comparison between r at isolated aorta and cultured aortic cells. Cell Calcium 2012; 52:413-421
11. Kimura K, Ito M, Amano M, et al: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273:245-248
12. Swä rd K, Mita M, Wilson DP, et al: The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5:66-72
13. Cavarape A, Bauer J, Bartoli E, et al: Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: Role of rho-kinase. Nephrol Dial Transplant 2003; 18:1764-1 769
14. Sah VP, Seasholtz TM, Sagi SA, et al: The role of Rho in G protein-coupled receptor signal transduction. Annu Rev Pharmacol Toxicol 2000; 40:459-489
15. Uehata M, Ishizaki T, Satoh H, et al: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994
16. Fukumoto Y, Matoba T, Ito A, et al: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91:391-392
17. Bagi Z, Feher A, Cassuto J, et al: Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes-Role for Rho-kinase activation. Br J Pharmacol 2011; 163:1059-1068
18. Zhou Q, Mei Y, Sh oji T, et al: Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation 2012; 126:2236-2247
19. da Silva-Santos JE, Chiao CW, Leite R, et al: The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries. Crit Care Me d 2009; 37:1716-1723
20. Büyü kafar K, Arikan O, Ark M, et al: Upregulation of Rho-kinase (ROCK-2) expression and enhanced contraction to endothelin-1 in the mesenteric artery from lipopolysaccharide-treated rats. Eur J Pharmacol 2004; 498:211-217
21. Krejci V, Hiltebrand LB, Jakob SM, et al: Vasopressin in septic shock: Effects on pancreatic, renal, and hepatic blood flow. Crit Care 2007; 11:R129
22. Levy B, Collin S, Sennoun N, et al: Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. Intensive Care Med 2010; 36:2019-2029
23. O?Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210
24. Parker MM, Shelhamer JH, Natanson C, et al: Serial cardiovascular variables i n survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923-929
25. Gordon AC,Wang N.Walley KR,et al, The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock,Chest, 2012,142,593-605
26. Guyton AC, Coleman TG, Cowley AV Jr, et al: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52:584-594
27. Navar LG: The kidney in blood pressure regulation and development of hypertension. Med Clin North Am 1997; 81:1165-1198
28. Boffa JJ, Arendshorst WJ: Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J Am Soc Nephrol 2005; 16:117-124
29. Feng J, Ito M, Ichikawa K, et al: Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274:37385-37390
30. Kawano Y, Fukata Y, Oshiro N, et al: Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999; 147:1023-1038
31. Johnson RP, El-Yazbi AF, Takeya K, et al: Ca2+ sensitization via phosphorylation of myosin phosphatase targeting subunit at threonine-855 by Rho kinase contributes to the arterial myogenic response. J Physiol 2009; 587:2537-2553
32. Holmes CL, Landry DW, Granton JT: Science review: Vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 2003; 7:427-434
33. MacDonald JA, Borman MA, Murányi A, et al: Identification of the endogenous smooth muscle myosin phosphatase-associated kinase. Proc Natl Acad Sci USA 2001; 98:2419-2424
34. Murá nyi A, Derkach D, Erdodi F, et al: Phosphorylation of Thr6 95 and Thr850 on the myosin phosphatase target subunit: Inhibitory effects and occurrence in A7r5 cells. FEBS Lett 2005; 579:6611-6615
35. Eto M, Karginov A, Brautigan DL: A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes. Biochemistry 1999; 38:16952-16957
36. Eto M, Ohmori T, Suzuki M, et al: A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J Biochem 1995; 118: 1104 -1107
37. Hayashi Y, Senba S, Yazawa M, et al: Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa. J Biol Chem 2001; 276:39858-39863
38. Aiura K, Ueda M, Endo M, et al: Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Crit Care M ed 1995; 23:1898-1906
39. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758 Nível Superior